dm+d
3127006
Lactation Safety Information
Parenteral
Parenteral
Very limited published evidence indicates negligible levels in breast milk
If used as monotherapy do not resume breastfeeding until at least 24 hours after a dose, and monitor infant’s blood count
Discontinue breastfeeding if used in combination with other antineoplastics
3 August 2020
Topical
Topical
Imiquimod
Avoid use on large areas of skin and on the nipple and areola area
Avoid contact of the breastfeeding infant with treated areas
30 October 2020